Omesdafexor

  1. Home
  2. Wiki
Omesdafexor
Clinical data
Other namesMET409[1]
Legal status
Legal status
  • Investigational
Identifiers
  • N-[3-(1-cyclopropylpyrazol-4-yl)phenyl]-4-hydroxy-N-[[4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]cyclohexane-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC34H43N3O3
Molar mass541.736 g·mol−1
3D model (JSmol)
  • N(C[C@@H]1CC[C@H](CC1)C2=CC(C)=C(OC)C=C2)(C(=O)[C@@H]3CC[C@@H](O)CC3)C4=CC(=CC=C4)C5=CN(N=C5)C6CC6
  • InChI=1/C34H43N3O3/c1-23-18-28(12-17-33(23)40-2)25-8-6-24(7-9-25)21-36(34(39)26-10-15-32(38)16-11-26)31-5-3-4-27(19-31)29-20-35-37(22-29)30-13-14-30/h3-5,12,17-20,22,24-26,30,32,38H,6-11,13-16,21H2,1-2H3/t24-,25-,26-,32-
  • Key:RPBNLMPTFCTXRQ-RYYHSFPWNA-N

Omesdafexor (MET409) is a small-molecule farnesoid X receptor (FXR) agonist developed for nonalcoholic steatohepatitis and colitis.[2][3]

References

[edit]
  1. ^ Harrison, S. A.; Bashir, M. R.; Lee, K. J.; Shim-Lopez, J.; Lee, J.; Wagner, B.; Smith, N. D.; Chen, H. C.; Lawitz, E. J. (2021). "A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis". Journal of Hepatology. 75 (1): 25–33. doi:10.1016/j.jhep.2021.01.047. PMID 33581174.
  2. ^ Liu, Xueqing; O'Connell, Robert; Bendele, Alison; Walker, Melissa; Ohlsen, Connor; Govek, Steve; Nagasawa, Johnny; Douglas, Karensa; Milik, Angelica; Lu, Nhin; Qian, Jing; Ortiz, Alvaro; Chai, Pauline; Zook, Douglas; Lee, Kyoung-Jin; Smith, Nicholas; Wagner, Brandee; Song, Ken (February 2020). "P153 Met642, an Oral FXR Agonist, Improves Colitis Induced by Adoptive T-Cell Transfer". Gastroenterology. 158 (3): S11. doi:10.1053/j.gastro.2019.11.062.
  3. ^ "Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients". Retrieved 2 December 2023.